

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*The forward-looking statements made in this announcement relate only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our directors and/or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.*



**CStone Pharmaceuticals**

**基石藥業**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2616)**

## **VOLUNTARY ANNOUNCEMENT INCLUSION OF CSTONE AS A CONSTITUENT STOCK OF HANG SENG COMPOSITE INDEX**

This announcement is made by CStone Pharmaceuticals (the “**Company**” or “**CStone**” and together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has been selected and will be included as a constituent stock of the Hang Seng Composite Index (“**HSCI**”), with effect from September 6, 2021.

HSCI offers a comprehensive Hong Kong market benchmark that covers about top 95th percentile of the total market capitalization of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited. Adopting the free float-adjusted market capitalization methodology, HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks. The inclusion of CStone in the HSCI indicates that the Company’s stocks are eligible for trading via the Hong Kong Stock Connect, which is a channel for stock trading and investment between Hong Kong and the investors in the capital market of Mainland China.

The Board is of the view that the Company’s inclusion in the market benchmark index represents the capital market’s recognition of the Group’s business performance and growth outlook. The Board believes that such selection will help facilitate the expansion of the Company’s shareholder base and increase the trading liquidity of the shares of the Company, resulting in realization of the value of investment in the Company and further enhancement of the Company’s reputation in the capital market and the Group’s brand awareness.

Since the establishment in 2015, CStone has been focusing on high incidence cancers in China and has developed a variety of drug candidates to bring transformative treatments to patients and become one of the few companies in the industry that are commercializing assets globally. In 2021, CStone launched two products successfully in Mainland China and Taiwan, China, and expects to receive several new drug approvals this year. Currently, the Company is working closely with its partners Pfizer and EQRx to advance the clinical development and commercialization of immuno-oncology products including sugemalimab in Mainland China and overseas to maximize their overall value. The

inclusion in the HSCI may continue improve the Company's visibility and access to the capital market and will benefit the sustainable growth of the Company in the long term.

## **About CStone**

CStone is a biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The Company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received three drug approvals in Greater China, including two in mainland China and one in Taiwan. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.

For more information about CStone, please visit: [www.cstonepharma.com](http://www.cstonepharma.com).

By Order of the Board  
**CStone Pharmaceuticals**  
**Dr. Frank Ningjun Jiang**  
*Chairman*

Suzhou, the People's Republic of China, August 20, 2021

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Frank Ningjun Jiang as Chairman and executive Director, Dr. Wei Li, Mr. Qun Zhao, Mr. Yanling Cao, Mr. Xianghong Lin and Mr. Edward Hu as non-executive Directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive Directors.*